stockrowGenmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.
- Revenue
- +24.9%
- EPS
- −9.26%
- Free cash flow
- −7.69%
Quarter to June 2026, against a year earlier
Follow GMAB
Alert me
Genmab A/S Sponsored ADR (GMAB) Return on invested capital
Genmab A/S Sponsored ADR's return on invested capital over the twelve months to 30 June 2026 was 6.99%, down 0.1 percentage points from fiscal 2025 (7.08%). Over the past ten years it has ranged from 0.00% (fiscal 2017) to 116.5% (fiscal 2020); the current reading is higher than 30% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 7.08% | (20.75) |
| FY2024 | 27.8% | (67.87) |
| FY2023 | 95.7% | 26.26 |
| FY2022 | 69.4% | 11.66 |
| FY2021 | 57.8% | (58.76) |
| FY2020 | 116.5% | 65.94 |
| FY2019 | 50.6% | 5.39 |
| FY2018 | 45.2% | 45.21 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 85.2% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 59.4% |
| INCY Incyte Corporation compare | 21.6% |
| GMAB Genmab A/S Sponsored ADR | 6.99% |
| RPRX Royalty Pharma PLC compare | 5.24% |
| RVMD Revolution Medicines, Inc. compare | 0.00% |
| BNTX BioNTech SE Sponsored ADR compare | −34.3% |
| ROIV Roivant Sciences Ltd. compare | −34.5% |
| INSM Insmed, Inc. compare | −247.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on GMAB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement